Erbitux Approval For Colorectal Cancer Sought In Japan
This article was originally published in PharmAsia News
Executive Summary
Merck KGaA has requested a priority review in its regulatory submission for the biologic Erbitux (cetuximab) to the Japanese Pharmaceuticals and Medical Devices Agency, the firm told "The Pink Sheet" DAILY